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Abstract
Background: Adjuvant treatment with radioactive iodine (RAI) is often considered in the treatment of well-differentiated
thyroid carcinoma (WDTC). We explored the recollections of thyroid cancer survivors on the diagnosis of WDTC, adjuvant
radioactive iodine (RAI) treatment, and decision-making related to RAI treatment. Participants provided recommendations
for healthcare providers on counseling future patients on adjuvant RAI treatment.
Methods: We conducted three focus group sessions, including WDTC survivors recruited from two Canadian academic
hospitals. Participants had a prior history of WDTC that was completely resected at primary surgery and had been offered
adjuvant RAI treatment. Open-ended questions were used to generate discussion in the groups. Saturation of major themes
was achieved among the groups.
Findings: There were 16 participants in the study, twelve of whom were women (75%). All but one participant had received
RAI treatment (94%). Participants reported that a thyroid cancer diagnosis was life-changing, resulting in feelings of fear and
uncertainty. Some participants felt dismissed as not having a serious disease. Some participants reported receiving
conflicting messages from healthcare providers on the appropriateness of adjuvant RAI treatment or insufficient
information. If RAI-related side effects occurred, their presence was not legitimized by some healthcare providers.
Conclusions: The diagnosis and treatment of thyroid cancer significantly impacts the lives of survivors. Fear and uncertainty
related to a cancer diagnosis, feelings of the diagnosis being dismissed as not serious, conflicting messages about adjuvant
RAI treatment, and treatment-related side effects, have been raised as important concerns by thyroid cancer survivors.
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Introduction
The incidence of thyroid cancer is rising in Canada [1] and the
United States [2–4]. In the United States, the incidence of thyroid
cancer has increased from 3.6 per 100,000 persons in 1973 to 8.7
per 1000,000 in 2002, representing a 2.4-fold increase [3]. Also, in
the United Kingdom, age-standardised incidence rates for thyroid
cancer have nearly doubled from 1.4 to 2.6 per 100,000 persons
between 1975 and 2005 [5]. The case fatality rate of thyroid
cancer is low, as the annual number of deaths due to thyroid
cancer is approximately 5% of the annual number of newly
diagnosed cases in the United States [2]. Recent major and
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been reported in Europe over the period of 1991 to 2002 [6]. The
most frequent histologic subtype of thyroid carcinoma is papillary,
accounting for approximately 80 percent of cases, followed by
follicular carcinoma (collectively referred to as well-differentiated
thyroid carcinoma, WDTC) [7,8]. In early stage papillary thyroid
carcinoma, Hay et al. from Mayo Clinic Rochester have reported
a 20-year case fatality rate of less than 1% [9–11]. As the incidence
of thyroid carcinoma is rising and the disease-related mortality
rate is low, the long-term quality of life of survivors is an important
consideration.
Currently recommended treatments of WDTC include thyroid-
ectomy and thyroid hormone, sometimes followed by post-surgical
radioactive iodine (RAI) remnant ablation (depending on patient
and disease features) [12–18]. Various bodies have provided
clinical practice guidelines on management of thyroid cancer, with
recommendations for adjuvant radioactive iodine treatment in
early stage papillary cancer ranging from no radioactive iodine for
very early stage disease (such as unifocal tumors ,1c m i n
diameter) to dose activities of 29.9 mCi to100 mCi [12–18]. In a
recent prospective registry study of well-differentiated thyroid
cancer, the National Thyroid Cancer Treatment Co-operative
Group reported that radioactive iodine treatment had been
administered in 62% to 75% of individuals in their study cohorts
[19].
There are no long-term randomized controlled trials examining
the efficacy of RAI remnant ablation in thyroid cancer and there
are conflicting reports in observational studies on the benefits of
adjuvant radioactive in reducing the risk of thyroid cancer-related
mortality and recurrence in early stage disease [20–22]. Using
propensity analysis in prospective registry data, the National
Thyroid Cancer Treatment Co-operative Group did not observe a
significant treatment benefit of adjuvant radioactive iodine
treatment in patients classified as having post-surgical Stage 1
disease (using a study-specific classification system), for the
outcomes of overall survival, disease-specific survival, and
disease-free survival, respectively [19]. However, this registry
study is limited by relatively short mean follow-up period of
3 years [19]. In a recent physician survey performed in Canada
and the United States, physicians’ recommendations on the use of
adjuvant RAI treatment in early stage papillary thyroid cancer
were highly variable, with some of the variability explained by
region of practice, physician subspecialty, and academic versus
non-academic affiliation [23]. In this survey, strong physician
support for the use of adjuvant radioactive treatment in early stage
thyroid carcinoma was related to beliefs that this intervention: 1)
decreases disease-related mortality and recurrence, and 2)
facilitates disease follow-up at low risk of adverse effects [24].
In several recent studies, thyroid cancer survivors have been
reported to have impairments in long-term health-related quality
of life, in spite of cure of disease [26–28]. The reasons for impaired
quality of life in thyroid cancer survivors in whom the cancer has
been cured are not well-understood are not related to thyroid
stimulating hormone (TSH) levels [27]. It is not known if a history
of RAI treatment has any impact on future long-term quality of life
of WDTC survivors nor how the current controversy about the
utility of adjuvant radioactive iodine in early stage WDTC impacts
patients’ perceptions about RAI treatment decision-making.
We conducted a qualitative study exploring patients’ percep-
tions of the WDTC, with particular emphasis on the events related
to adjuvant RAI treatment. In general, we asked thyroid cancer
survivors what information about their experience would be
important to share with future patients and healthcare providers.
We explored their recollections of counseling encounters with
healthcare providers related to decision-making regarding adju-
vant RAI treatment. WDTC survivors provided us with
recommendations on how RAI treatment-related counseling may
be improved for future patients.
Methods
Objectives
Our objective was to explore, from the perspective of thyroid
cancer survivors, the experience of a diagnosis of thyroid
carcinoma, counseling and decision-making related to adjuvant
radioactive iodine treatment, and any short- or long-term
consequences of such treatment. We hypothesized that some
thyroid cancer survivors would have received conflicting messages
about the utility of RAI treatment in early stage WDTC and that a
minority of individuals would have suffered side effects from the
treatment.
Participants
All participants were recruited from University Health Network
and Mount Sinai Hospital in Toronto, Canada through poster
advertisements in Endocrinology, Otolaryngology, Head and
Neck Surgery, and Endocrine Oncology clinics. Participants were
eligible if they had well-differentiated papillary or follicular thyroid
carcinoma (or variant) that was completely resected at primary
surgery and if they were offered adjuvant RAI (regardless of
whether or not RAI was ultimately accepted and where the
treatment was performed). The definition of completely resected
thyroid cancer was the lack of known visible residual cancer
identified at the time of surgery.
Description of procedures or investigations undertaken
An in-depth qualitative study was performed, using focus groups
to allow participants to build upon ideas raised by other
participants [29–32]. We conducted three focus group sessions
in July, 2007. Each group included five or six WDTC survivors,
for a total of 16 participants. All sessions were moderated by a
medical facilitator and a qualitative researcher. Participants were
instructed that the main topic of interest for the group was the
experience of counseling, decision-making, and treatment related
to radioactive iodine but that participants could discuss any
component of the disease trajectory if they wished. Each session
began with a general, in-depth discussion on the personal
experience of thyroid cancer, followed by five questions (Appendix
S1). The questions for discussion were generated by a panel of
content experts including endocrinologists (AMS, SRG, JG SE),
radiation oncologists (JDB, RWT), head and neck oncology
surgeons (DPG, LR), and three thyroid cancer survivors
(Appendix S1). The questions were reviewed by experts in
qualitative research (MAO, LM, SS), a psychiatrist (SA), and
experts in health research (AG, LT). The questions were presented
to participants in the focus group sessions to generate discussions
of personal experiences of survivors. The proceedings were audio
recorded and transcribed per verbatim (by AN). Additional notes
were taken during the sessions by two observers (AMS and AN).
The practice of coding transcribed data involved initially
exploring for responses related to the general research questions
and then coding the data for respondents’ meanings, feelings, and
actions [33]. The content of the transcripts was systematically
coded using N Vivo 7.0 software (by LM). The data were
examined for processes and relationships between specific events
and general processes [33]. Coding data led to new categories and
more data were collected on the developing categories, upon
reviewing all transcripts [33]. Newly gathered data from each
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data from prior sessions and their coding [33].
The data analysis was based in grounded theory [34,35], which
relies on the process of constant comparison of qualitative data
(statements) retrieved from participants. The constant comparative
method is comprised of four stages: 1) comparing incidents
(participant statements) applicable to each theme that emerges
from the data, 2) integrating themes and their properties, 3)
delimiting the theory arising from the themes, 4) and reporting the
theory [36]. Theoretical saturation of themes is achieved when no
new insights are obtained, no new themes identified, and no issues
arise regarding a category of data, in spite of replicating the study
conditions (eg. analyzing data from additional focus group
sessions) [36]. In this study, the comparative analyses were
performed by LM; the identification of themes and theories was
performed by LM. The identified themes from the qualitative
analysis were then reviewed with an observer with content
expertise who was present at all sessions (AMS). The clinical
context of themes was clarified by discussion between LM and
AMS and any queries were clarified by consulting the original
transcripts of sessions. There was final consensus on the identified
themes by LM and AMS. The identified themes were also verified
by another observer (AN) who was present at all sessions.
Complete agreement was achieved on identified themes by the
qualitative researcher conducting the sessions and analyzing the
data (LM) and the two observers (AMS, and AN). Theoretical
saturation of themes was achieved in this study upon analysis of
the data from the three sessions. No a priori sample size was
required for this qualitative study [37], as adequacy of sample size
was defined by saturation of identified themes [36,37].
Descriptive information on patient characteristics was self-
reported by initial telephone interview and self-administered,
written questionnaire. The number of individuals reporting one or
more RAI treatment-related side effects in the focus group sessions
was quantified, using data from the original transcripts. The side
effects were quantified by AN, reviewed by AMS, and any clinical
queries were resolved by reviewing the original transcripts.
Agreement was achieved on the specific side effects identified
during the sessions by AMS and AN. We did not quantify other
conceptual themes identified in the focus group discussions.
Clinical and pathological data was verified in the University
Health Network and Mount Sinai Hospital medical records, if
allowed by the participant and if the data was available.
Ethics
Written, informed consent was obtained for participation in the
study from all participants and the study was approved by the
University Health Network and Mount Sinai Hospital Ethics
Review Boards. In an effort to ensure that participants felt
comfortable to freely discussing aspects of their medical care in a
safe research environment, participants were provided the option
of declining consent for the investigators to review of their
individual medical records or to have contact with their treating
physicians.
Results
Description of the Participants
There were 16 participants in the study, twelve of whom (75%)
were women. The mean age of participants was 44 years (range 28
to 75 years). Approximately three-quarters of participants had a
university education or higher (12/16). The mean time since the
diagnosis of thyroid carcinoma was five years (range 2 to 8 years).
None of the participants were known to have a history of their
thyroid cancer presenting with distant metastases. For the 10
individuals for whom pathologic data was available, primary
tumor sizes ranged from 1 to 4 cm, regional nodal metastases were
known at time of initial surgery in two individuals, and three
individuals had some degree of extra-thyroidal invasion of the
primary tumor. The majority of participants (94%, 15/16) had
received RAI treatment and none received external beam
radiation therapy. Thyroid hormone was withdrawn prior to all
RAI treatments. For the 10 individuals for whom data was
available on the initial RAI treatment dose, the activities ranged
from 100 to 106 mCi. Six individuals chose not to allow contact of
their treating physicians nor a review of their medical records to
avoid any potential risk of disclosure of their participation to them
or their institutions. Approximately one third of the participants in
the study had experienced recurrence of disease – five individuals
with local-regional recurrence and one who developed new lung
metastases. All individuals in whom WDTC recurred received a
second therapeutic dose of radioactive iodine.
Conceptual Themes Identified in the Focus Groups
The experience of being diagnosed with thyroid
cancer. There were multiple conceptual themes identified in
the focus group sessions (Table 1). In each session, participants
began with a discussion of what the diagnosis of thyroid cancer
meant to them. The experience of being diagnosed with thyroid
cancer was felt by everyone to be life-changing and was
accompanied by feelings of fear and uncertainty about the
future. Participants were generally aware that thyroid cancer-
related mortality rates are relatively low and received the message
from healthcare providers or the media that they had a ‘‘good
cancer.’’ However, the ‘‘good cancer’’ message was generally not
considered reassuring to survivors and was perceived as being
dismissive of the importance of the diagnosis. The need for life-
long follow-up and the possibility of future recurrence of disease
was troubling to survivors at the time of diagnosis. Sometimes,
participants reported feeling guilt and responsibility for their
diagnosis. Participants stressed the need for support from family,
friends, and their healthcare team, throughout the experience of
being diagnosed with thyroid cancer and undergoing the
associated treatments.
Counselling and decision-making related to adjuvant RAI
treatment. Participants generally reported that their primary
source of information and counselling on adjuvant RAI treatment
was their subspecialty physicians, such as endocrinologists, thyroid
surgeons, or radiation oncologists. Contradictory messages about
the utility of RAI treatment were received from their various
subspecialty healthcare providers as well as internet sources.
Participants who received information about current clinical
practice guideline recommendations (as they applied to their
individual case) from their thyroid cancer specialist, greatly valued
this communication. Participants generally considered their
primary care physicians less knowledgeable and less comfortable
counselling and managing thyroid cancer-related medical issues
than their subspecialty physicians. The internet was considered
easily accessible but the information available on it was generally
not considered relevant to their own disease and life situation.
Participants generally wished they had received more plain-
language information about the potential risks (short- and long-
term side effects), benefits, and uncertainties related to RAI
treatment at the time of decision making. For example, concerns
were expressed about any potential reproductive implications and
second primary cancers related to treatment. The desire for
detailed, quantitative statistics on disease prognosis and treatment
benefits was variable among participants, with some participants
Perspectives on Thyroid Cancer
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descriptive information specifically without numbers. The disclo-
sure of the possibility of thyroid cancer recurrence, in spite of RAI
treatment was highlighted by participants as being important.
Individuals who suffered a recurrence of thyroid cancer after initial
RAI treatment had difficulty rationalizing this outcome and
sometimes assigned self-blame. In general, the development and
dissemination of, written, plain-language information on risks,
benefits, and uncertainty about RAI treatment was endorsed by
the groups. The availability of web-based individualized informa-
tion was also endorsed by individuals who felt comfortable using
computers, although additional printed information was still
supported.
The desire for personal involvement in RAI decision-making
was variable, with some participants preferring to leave the
treatment decision to their healthcare providers and others
desiring to actively participate in choosing their treatment course.
Individuals who preferred an active role in making the decision on
RAI treatment, appreciated a sense of control over the experience
and feeling like nothing was being imposed on them. In contrast,
some individuals felt a sense of disempowerment about RAI
decision-making or feeling that there was really no other choice.
Some individuals felt most comfortable leaving the ultimate
decision on RAI treatment to their treating thyroid cancer
physicians, given the medical expertise and experience of their
healthcare providers. Only two of sixteen participants indicated
that they felt that the decision to accept or decline RAI treatment
was primarily their own (after initial consultation with their
respective physicians). Family and friends were identified as an
important source of emotional support throughout the disease
trajectory, although such individuals often lacked sufficient
information about thyroid cancer or its treatment.
Experiences after RAI treatment. The experience of
receiving RAI treatment was reported to be highly variable,
ranging from no perceived side effects, to some short- or long-term
side effects. More than half of RAI-treated participants (8/15)
reported one or more side effects which they attributed RAI
treatment, such as: a) short-term effects (nausea, painful salivary
gland swelling, changes in taste, sore throat, rash, hair thinning, or
menstrual changes) or b) chronic side effects (changes in taste, dry
eyes, gum and dental problems). Feelings of isolation at the time of
hospitalization for RAI treatment were also reported. The
presence of short- and long-term salivary or ocular symptoms
after RAI treatment was troublesome to those affected. Primary
care physicians and other healthcare professionals sometimes
failed to recognize adverse effects of RAI treatment at follow-up,
which was frustrating to affected individuals.
Thyroid hormone withdrawal prior to RAI treatment was
generally reported to be uncomfortable. Symptoms of thyrotox-
icosis due to long-term thyroid hormone suppressive therapy were
variable, but when present, palpitations, mood changes, and
difficulty concentrating were distressing and sometimes upset
relationships and work performance.
WDTC survivors’ suggestions for the type of information
to be shared by healthcare providers in counseling future
patients on RAI treatment. In an effort to improve and
standardize care for future WDTC patients, the focus group
participants provided several key recommendations for healthcare
providers to incorporate in counseling patients with WDTC about
RAI treatment (Table 2).
A) EXPLAIN THE RATIONALE FOR RAI REMNANT
ABLATION: Participants felt it was important for physicians
to explain the rationale for (or against) adjuvant RAI
treatment in their particular case.
B) EXPLAIN THE POTENTIAL BENEFITS AND RISKS
OF RAI TREATMENT AND RELATED UNCERTAIN-
TY: Participants believed it was important for thyroid cancer
specialists to clearly explain, in plain language, the potential
benefits as well as the short- and long-term potential adverse
effects of RAI treatment and any treatment-related uncer-
tainty (due to a limited high quality evidence) or existing
controversy. The provision of written plain language
information on risks and benefits of RAI treatment was
Table 1. Themes identified in the focus group sessions with thyroid cancer survivors.
Themes Details
The life-changing experience of a thyroid cancer
diagnosis
1. The experience of being diagnosed with thyroid cancer changed the lives and the outlook on
life of survivors.
2. The diagnosis was followed by feelings of fear and uncertainty about the future.
3. Being told that thyroid cancer was a ‘‘good cancer’’ was generally not reassuring to survivors,
and was accompanied by feelings that their diagnosis being dismissed as unimportant.
4. Support from family, friends, and healthcare providers was appreciated.
The experience of receiving counseling and decision-
making on adjuvant radioactive iodine (RAI) treatment
1. The primary information source related to thyroid cancer treatment, including RAI, was
thyroid cancer specialty physicians.
2. Contradictory messages about the utility of adjuvant RAI treatment were received from
physician and internet sources.
3. Plain-language information about the risks, benefits, and uncertainty about RAI treatment
was desired.
4. The desire for numerical data on disease prognosis and treatment benefits was variable.
5. Information available on the internet was not considered sufficiently individually relevant.
6. Individuals varied in their desire to be involved in decision making on RAI treatment.
The experience after RAI treatment 1. More than half of participants (8/15) reported some short- or long-term emotional of physical
negative effects attributed to RAI treatment.
2. Side-effects due to RAI treatment were not always recognized by treating physicians at
follow-up.
doi:10.1371/journal.pone.0004191.t001
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and second cancer risks were identified as a couple of key
areas for discussion.
C) TEAM-BASED THYROID CANCER CARE AND
AVOIDANCE OF CONFLICTING RECOMMENDA-
TIONS AMONG HEALTHCARE PROVIDERS: A multi-
disciplinary team-based, individualized, approach to treat-
ment of WDTC was favoured by participants. Open
communication among speciality healthcare providers and
individualized treatment recommendations were valued.
Some participants expressed a desire to play an active role
in the informed decision-making process, whereas others felt
comfortable with following their physicians’ recommenda-
tions.
D) INFORMATION SHARING ABOUT CURRENT CLIN-
ICAL PRACTICE GUIDELINE RECOMMENDA-
TIONS: Participants greatly valued the expertise of the
authors of clinical practice guidelines and indicated that it is
important for healthcare providers to explain current
guideline recommendations to future patients being offered
RAI treatment. A discussion of the application of the clinical
practice guidelines to the individual case was valued.
Long-term follow-up and care of WDTC
survivors. Participants who reported treatment-related side
effects that were not recognized or acknowledged by their
healthcare providers reported feelings of frustration. Thus, some
individuals sometimes sought second opinions from other thyroid
cancer specialists. Thus, an important message from thyroid
cancer survivors was the need for legitimization of their treatment-
related symptoms at long-term follow-up. Furthermore,
participants highlighted the need for long-term support for not
only themselves, but also their family, throughout the disease
trajectory. Participants stressed the need for more clinical research
in the treatment and outcomes in well-differentiated thyroid
cancer.
Discussion
In summary, the participants in our study reported a significant
impact of a diagnosis of thyroid carcinoma and its treatments on
their lives. The key source of information about WDTC and its
treatment that patients identified was their thyroid cancer
subspecialty physicians (such as endocrinologists, surgeons, or
radiation oncologists). The internet was not deemed an important
source of individually relevant information about thyroid cancer,
consistent with recent reports that internet information on thyroid
cancer is often outdated and incomplete [38]. Fear and
uncertainty related to a thyroid cancer diagnosis, a perception of
the diagnosis being dismissed as not ‘‘serious,’’ controversies and
conflicting messages about adjuvant RAI treatment, and treat-
ment-related side effects, were challenges reported by participants.
The amount of detailed information that was desired by
participants in counselling encounters, particularly relating to
‘‘the numbers’’ (statistics on prognosis and treatment benefit) was
highly variable. Furthermore, the desired degree of active
involvement in choosing RAI treatment was highly variable
among participants. An approach of evidence-informed team-
based, individualized thyroid cancer care was favoured by
participants. Based on their unique perspective, participants in
our study provided us with some recommendations to improve
patient counselling on adjuvant RAI treatment for WDTC. Also,
participants highlighted the importance of recognition and
validation of treatment-related side effects by healthcare providers
at long-term follow-up. The importance of support for family
members was also ascertained. A need for more clinical research in
the treatment of WDTC was also affirmed.
The strength of this study is its qualitative design with an in-
depth examination of the experience of thyroid cancer and its
treatment, from the perspective of survivors. Our reasons for
choosing focus group methodology for this study are similar to
those expressed by Allen et al. in studying breast cancer survivors
who received adjuvant treatment [39]. These reasons include: a)
inclusion of multiple participants to allow a range of perspectives
to be expressed about a phenomenon, b) allowing each participant
to contemplate the extent to which he/her experience is similar or
different to other group members, and c) allowing participants
leeway to express perceptions and feelings that may lead to
discussion themes and ultimately illuminate the key aspects of the
phenomenon of interest, and d) the collective context of focus
groups enabling identification of pertinent themes. The identifi-
cation of pertinent themes may take longer to emerge through
individual interviews (relative to focus groups) and may not be
revealed in a structured questionnaire [39].
Many of the themes extracted from our discussions with thyroid
cancer are similar to themes reported in qualitative studies of other
patient groups. For example, Allen et al. reported that women with
a history of early stage breast cancer who received adjuvant
treatment expressed fears about disease recurrence and
Table 2. Recommendations of focus group participants for physician counseling of future patients about adjuvant radioactive
iodine (RAI) treatment.
Themes Details
The rationale for adjuvant RAI treatment An explanation for the rationale for (or against) adjuvant RAI treatment was desired at the
individual case level
The potential benefits and risks of adjuvant RAI treatment and related
uncertainty
Plain language information was desired on the benefits and risks of RAI treatment as well ass
any uncertainty due to limited high quality evidence or controversy. Potential reproductive
implications (for those interested in this) and risk of second primary cancers were
emphasized as important areas for discussion. The importance of highlighting that disease
may recur in spite of RAI treatment was also suggested.
Team-based thyroid cancer care and avoidance of conflicting
recommendations among healthcare providers
A multi-disciplinary team-based, individualized, approach to treatment of WDTC was
favoured by most participants. Open communication among speciality healthcare providers
and individualized treatment recommendations were valued.
Information sharing about current clinical practice guidelines A discussion about current clinical practice guidelines as they relate to the individual case
was valued by participants.
doi:10.1371/journal.pone.0004191.t002
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expressed by thyroid cancer survivors in our study. It is interesting
to note that conflicting messages about treatment were not
reported in the study by Allen et al. in the field of early stage breast
cancer, likely reflecting the wealth of high quality randomized
controlled trial data available in that field. In contrast, in the field
of early stage thyroid cancer, conflicting findings of observational
studies on adjuvant RAI treatment [22], may contribute to the
mixed messages about the utility of treatment.
The themes relating to an individual’s role in cancer treatment
decision making in this study were similar to those previously
reported for other disease conditions. In our study, physicians’
opinions about their medical condition and potential treatments
were highly valued by participants. However, most participants
reported thattheywerenotinvolvedindecisionmakingonadjuvant
RAI treatment. Of note, patient preference for involvement in
treatment decision making was highly variable, with some
individuals strongly preferring an active role and others preferring
to leave the decision to their physician. In a qualitative study
examining women’s perceptions about treatment decision- making
for ovarian cancer, Elit et al. [40] also reported that most
participants did not feel actively involved in a shared treatment
decision-making process. In terms of treatment decision making, in
a qualitative study of women aged 65 years and older who were
diagnosed with breast cancer, Kreling et al. also reported that many
women felt they had no choice and followed physicians’ treatment
recommendations about treatment [41]. In a focus group study of
cardiac patients aged 56 years and older, participants indicated that
they preferred to follow the cardiologist’s recommendation for
treatment, based on their medical expertise [42], similar to a view
on treatment decision making expressed by some of our
participants. Similarly, in a recent qualitative and quantitative
study of disease-free rectal cancer survivors and oncologists, Pieterse
et al. reported that the majority of patients and clinicians thought
that not all patients are able to participate in treatment decision
making [43]. In this study of rectal cancer survivors, both patients
and clinicians also thought that the clinicians are not always able to
weigh the pros and cons of treatment for patients [43]. Pieterse et al.
concluded that clinicians should extensively inform patients about
their treatment options [43]. The patients in our study also
recommended that physicians should explain the potential benefits
and risks of treatment even though many of them wanted their
physician to provide a treatment recommendation. In reviewing the
results of our study and the literature, it appears that individual
preferences on involvement treatment decision making are highly
variable, although in general, information about the pros and cons
of treatment are strongly desired by individual patients.
Some short- and long-term side effects of RAI treatment were
acknowledged by participants in this study. Examples of long-term
side effects attributed to RAI treatment included changes in taste,
dry eyes, gum or dental problems. The issue of long-term and late
side effects experienced by cancer patients is receiving increased
recognition in the cancer care literature. The Institute of Medicine
published an extensive report, ‘‘From Cancer Patient to Cancer Survivor:
Lost in Transition’’ [44]. One of the key recommendations in this
report was that ‘‘patients completing primary treatment should be
provided with a comprehensive care summary and follow-up plan
that is clearly and effectively explained’’ [44]. One component of
such a survivorship plan is a treatment summary that includes an
explanation of expected recovery of acute treatment side effects [44].
Another component ofa survivorship planisanongoing careplanso
that cancer survivors receive coordinated care from team members
knowledgeable about the disease process and treatment-related side
effects [44]. In applying these recommendations from the Institute of
Medicine to the care of thyroid cancer survivors, it is hoped that the
uncertainties and potential anxiety related to the disease course and
any treatment-related side effects may be reduced.
Limitations
There are several limitations to our study. Firstly, the
generalizability of our findings maybe limited because the
participants were recruited from only two tertiary/quaternary
care academic institutions in the same city. The demographic
characteristics of our participants (approximately three-quarters
women and mean age in the mid-forties), are in keeping with
general population thyroid cancer statistics (76% of new thyroid
cancer cases are in women in Canada [1] and the mean age of
diagnosis in the Surveillance, Epidemiology, and End Results
Program in the United States is 46 years [4]). All participants in
this study were English-speaking and many of them were highly
educated, which may limit the applicability of our findings to other
populations. Moreover, the prevalence of disease recurrence in our
study group (approximately one-third), was higher than one would
expect expected for early stage papillary thyroid cancer (an
average cumulative incidence of 9.3% at 10 years) [22]. In our
study, more than half of participants reported one or more short-
or long-term side effects attributed to RAI treatment, which is
higher than the 29% rate of short-term side effects reported in the
thyroid hormone withdrawal group for a recent efficacy study of
remnant ablation [45]. It is possible that there may be some
recruitment bias in our sample as individuals with recurrent or
more complex disease features may have been more likely to be
followed in the tertiary/quaternary care environment of our
institutions than in the community. Also, some individuals who
were initially treated at other institutions may have been referred
to our institution for treatment of recurrent disease. Some of the
treatment-related side effects reported by participants may have
been a reflection of more intensive therapy administered in a
tertiary care environment where complex cases are often seen.
Also, it is possible that participants who had particularly negative
experiences after their diagnosis of thyroid carcinoma or its
treatment chose to participate in this study, potentially resulting in
some biased findings. Furthermore, it is important to note that all
participants in our study who were treated with radioactive iodine
underwent thyroid hormone withdrawal, so the RAI treatment
experiences may not be generalizable to patients pre-treated with
recombinant human thyrotropin prior to radioactive iodine
treatment. Our data are also limited by the lack of access to
original pathologic data and RAI treatment details for all
participants as some participants preferred for us not to access
their medical records not contact their treating physicians, in order
to ensure a safe environment for discussion of sensitive issues
related to their medical care. Another limitation in this study, is
that in contrast to a purely quantitative approach, such as a
questionnaire, data were extracted from a relatively small number
of subjects (albeit sufficient for qualitative analysis), and the results
cannot be subjected to a statistical test. Thus, quantitative studies
may be useful to determine the prevalence of some of the
phenomena identified. For example, with respect to treatment-
related side effects, a larger study including patients from multiple
institutions may be instructive in better identifying the treatment-
related risk relative to dose activity of RAI received.
Concluding remarks and future research directions
In the current study, we have tried to fulfil the general aim of
qualitative research to enhance the awareness of social dynamics
in the clinical setting [46], in this case specifically related to the
care of individuals with thyroid cancer. We have also highlighted
Perspectives on Thyroid Cancer
PLoS ONE | www.plosone.org 6 January 2009 | Volume 4 | Issue 1 | e4191the need for improvement in knowledge translation about
adjuvant radioactive iodine to individuals being offered this
treatment. In terms of future research and care directions, the
desire for more information and stronger evidence about
treatment benefits and adverse effects emerged from the focus
groups that we conducted. A long-term randomized controlled
trial of adjuvant RAI remnant ablation in early stage WDTC
would be of great value to generate information of this kind and
better inform clinical practice. Moreover, in the mean time,
reasonable disclosure of treatment risks, benefits, and uncertainties
of adjuvant RAI to future patients should be emphasized, with
sensitivity to the individual’s specific information needs and
avoidance of conflicting messages among healthcare providers.
Healthcare providers treating thyroid carcinoma should be aware
of the existing clinical practice guidelines relating to the use of
adjuvant RAI treatment, and disclose the current recommenda-
tions, as they relate to the individual patient’s case. Davis et. al
have previously reported that reasons for variable implementation
of clinical practice guideline recommendations may include the
following: the qualities of the guidelines, characteristics of the
health professional, characteristics of the practice setting, incen-
tives, regulation, and patient factors [47]. Furthermore, Davis et
al. have found that effective strategies for the implementation of
clinical practice guideline recommendations may include: remind-
er systems (such as posters, laminated cards, or structured disease
management reminder sheets), academic detailing of an individual
physicians by other physicians, and multifaceted interventions
(involving two or more interventions such as mailed materials with
follow-up phone calls, presentations at meetings, and follow-up
meetings with physicians) [47]. Perhaps in the future in the field of
thyroid cancer, it may be feasible for organizations publishing
clinical practice guidelines to consider developing abbreviated
reminder cards or disease management reminder sheets that may
enable clinicians to implement current recommendations. How-
ever, at present, conflicting observational evidence and the lack of
long-term randomized controlled trials on interventions for the
treatment of thyroid cancer, makes evidence interpretation and
application of clinical practice recommendations very challenging.
Open communication between healthcare providers and
patients is an important priority in medical care. Yet, communi-
cation with patients about complex treatment interventions may
be challenging for physicians. Decision aids are tools or
instruments used to inform patients about available treatment
options, including evidence about benefits and risks of interven-
tions [48]. Decision aids facilitate evidence-based patient choice
[49–51] and are useful in the clinical setting when there is more
than one reasonable treatment option [52]. In a recent Cochrane
systematic review, decision aids were found to improve general
patient knowledge, result in more realistic patient treatment
expectations, increase the proportion of people active in decision
making, and reduce indecisiveness, when compared to usual care
[53]. In oncology, decision aids have been typically used to
supplement and complement the informal counseling provided by
a healthcare provider [54]. For example, in the adjuvant setting, a
patient who has had complete resection of malignancy but is at risk
for future recurrence; decision aids may facilitate informed
decision making about more than one adjuvant treatment
alternative, including declining therapy. Decision aids for adjuvant
therapy in breast cancer have been successfully developed and
tested [55–62]. We are currently in the process of developing a
computerized decision aid for counselling individuals with early
stage papillary thyroid carcinoma on the options of accepting or
declining adjuvant radioactive iodine treatment. The intention of
such a decision aid is not to replace the importance of physician
counselling, but instead to supplement it and facilitate further
discussion between healthcare providers and patients. It is also
important to highlight that communication between thyroid
cancer survivors and their healthcare provider should be
facilitated, not only at points in therapeutic decision making, but
throughout the entire disease trajectory. The thyroid cancer care
team should enable discussions of any disease or treatment-related
concerns and address any ongoing needs for emotional support of
survivors. The application of survivorship care plans, as outlined
by the Institute of Medicine [44], may be of great value in the field
of thyroid cancer. The impact of knowledge translation strategies
as outlined herein on the physical, mental, and emotional health of
thyroid cancer survivors deserves further study in the future.
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